Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States

Author:

Jia Xiaoying¹,Zhao Yang²,Carrico Justin³,Brodtkorb Thor-Henrik⁴,Mendelsohn Alan M.²,Lowry Simon²,Feldman Steve⁵,Wu Jashin J.⁶,Armstrong April W.⁷

Affiliation:

1. RTI-Health Solutions, Manchester, UK;

2. Sun Pharmaceutical Industries, Princeton, NJ, USA;

3. RTI-Health Solutions, Research Triangle Park, NC, USA;

4. RTI-Health Solutions, Ljungskile, Sweden;

5. Wake Forest School of Medicine, Winston-Salem, NC, USA;

6. Dermatology Research and Education Foundation, Irvine, CA, USA;

7. Southern California Clinical and Translational Science Institute, Los Angeles, CA, USA

Publisher

Informa UK Limited

Subject

Dermatology

Link

Reference43 articles.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

5. Tildrakizumab: interpreting the data;British Journal of Dermatology;2021-05-25